Razelle Kurzrock, Founding Director of Michels Rare Cancers Research Laboratories at the Medical College of Wisconsin and Co-Founder and Board Member at CureMatch, shared a post on X:
“ADCs are like Trojan horses. They exploit cell surface receptors to internalize chemo payloads into cancer cells. Next generation therapies. Enhertu shows responses in leptomeningeal disease.”
Title: Trojan Horses at Leptomeningeal Cellular Gates: Antibody–Drug Conjugates Deliver Cytotoxic Payloads
Authors: Mina Nikanjam, Razelle Kurzrock
Read The Full Article
More posts featuring Razelle Kurzrock on OncoDaily.